The rankings of the top pharmaceutical companies in the world in 2017 presented a mixed picture, with stability for some of the 25 largest firms as others saw their value fall.
Roche has announced that its phase 3 IMpower130 study met its co-primary endpoints of overall survival and progression-free survival in non-small cell lung cancer (NSCLC).